C3orf58 Inhibitors
C3orf58 inhibitors encompass a variety of chemical compounds that intervene at different points within critical cellular signaling pathways, ultimately leading to the suppression of C3orf58's functional activity. Rapamycin, for instance, targets the protein synthesis and cell growth regulator mTOR, which may result in the downregulation of C3orf58 if it is under mTOR regulation. Similarly, Staurosporine's broad kinase inhibition might lead to reduced phosphorylation of proteins in shared pathways with C3orf58, thereby indirectly diminishing its function. LY 294002 and Wortmannin exert their inhibitory influence by obstructingthe PI3K/Akt signaling pathway, potentially reducing the expression or activity of proteins like C3orf58 that may depend on these survival signals. Compounds such as PD 98059, U0126, and SB 203580 specifically target the MAPK pathway at different junctures: PD 98059 and U0126 by inhibiting MEK and thereby potentially reducing ERK-dependent regulation of C3orf58, and SB 203580 by inhibiting p38 MAP kinase, which could decrease downstream signaling affecting C3orf58's stability.
In the realm of cell cycle and stress response, ZM-447439, Alisertib, and Roscovitine introduce a targeted disruption. ZM-447439 and Alisertib inhibit Aurora kinases, which can interrupt mitosis and impact the regulation of cell cycle-dependent proteins such as C3orf58. Roscovitine impedes cyclin-dependent kinases, potentially leading to cell cycle arrest or altered transcription, resulting in a diminished presence or activity of C3orf58. Additionally, SP600125 inhibits the JNK pathway, which might impact JNK-mediated regulation of C3orf58, and Bortezomib disrupts proteasomal degradation, potentially stabilizing proteins that negatively regulate C3orf58. Through these precise actions, these inhibitors collectively contribute to the functional inhibition of C3orf58 by strategically targeting and disrupting the protein's regulatory networks and associated pathways without altering its transcription or translation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR, a key regulator of protein synthesis and cell growth. This can lead to the downregulation of proteins with rapid turnover, potentially including C3orf58 if it is mTOR-regulated. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor which can inhibit a broad range of protein kinases, possibly leading to the dephosphorylation and inactivation of proteins involved in the same pathways as C3orf58, indirectly inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that impedes the PI3K/Akt signaling pathway, which is involved in various cellular processes including growth and survival, potentially downregulating cellular levels of proteins like C3orf58. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 selectively inhibits MEK, which is upstream of ERK in the MAPK pathway. This inhibition can lead to reduced phosphorylation and activity of downstream targets, possibly affecting proteins that are regulated by the MAPK pathway, including C3orf58 if it is ERK-regulated. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAP kinase inhibitor which can suppress the kinase activity of p38, possibly leading to a decrease in downstream signaling and affecting the stability or activity of proteins such as C3orf58 if it is p38-regulated. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, leading to inhibition of the PI3K/Akt pathway. This can decrease survival signals and may indirectly decrease the stability or activity of proteins that rely on this pathway, such as C3orf58. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. This inhibition could decrease JNK-mediated signaling, potentially affecting the activity of proteins like C3orf58 if its function is modulated by JNK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, acting upstream in the ERK pathway. This suppression can lead to diminished ERK signaling, potentially downregulating proteins that are dependent on this pathway, such as C3orf58. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor which can disrupt mitosis, thereby potentially reducing the cellular levels of proteins with high turnover or those regulated during cell cycle progression, including C3orf58 if it is cell cycle-dependent. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor which prevents the degradation of ubiquitinated proteins, potentially leading to decreased levels of proteins that are negatively regulated by proteasomal degradation, including C3orf58. | ||||||